These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36030651)

  • 21. Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation.
    Gao Y; Tong M; Wong TL; Ng KY; Xie YN; Wang Z; Yu H; Loh JJ; Li M; Ma S
    ACS Nano; 2023 Nov; 17(22):22240-22258. PubMed ID: 37966480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
    Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
    J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. METTL3 and METTL14-mediated N
    Wu X; Zeng M; Wei Y; Lu R; Huang Z; Huang L; Huang Y; Lu Y; Li W; Wei H; Pu J
    Sci Rep; 2024 Mar; 14(1):6155. PubMed ID: 38486042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma.
    Wang J; Xiu M; Wang J; Gao Y; Li Y
    J Hematol Oncol; 2024 Sep; 17(1):78. PubMed ID: 39218945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
    Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
    J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
    Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
    Cancer Sci; 2024 Jul; 115(7):2220-2234. PubMed ID: 38623968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma.
    Zhuang M; Zhang X; Li LU; Wen L; Qin J
    Oncol Res; 2024; 32(8):1347-1357. PubMed ID: 39055886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
    Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
    Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
    Li H; Lan H; Zhang M; Zhao F; An N; Yi C
    Dig Dis Sci; 2023 Jul; 68(7):3070-3082. PubMed ID: 36680650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGF2BP3 suppresses ferroptosis in lung adenocarcinoma by m6A-dependent regulation of TFAP2A to transcriptionally activate SLC7A11/GPX4.
    Li P; Chu D; Ding G; Qin D; Bu Y; Tian B
    Mol Cell Biochem; 2024 Jul; ():. PubMed ID: 39026029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
    Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Sun X; Ou Z; Chen R; Niu X; Chen D; Kang R; Tang D
    Hepatology; 2016 Jan; 63(1):173-84. PubMed ID: 26403645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
    Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
    Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
    Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
    Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
    [No Abstract]   [Full Text] [Related]  

  • 37. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
    Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
    J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
    Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
    Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
    Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
    Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
    Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.